Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schwind

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|July 8, 2022
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantationLisa Herrmann, Lara Bischof, Donata Backhaus, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Blood Cancer Journal|April 30, 2021
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Annals of Hematology|August 31, 2020
Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AMLMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Bone Marrow Transplantation|November 19, 2020
ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
International Journal of Cardiology. Heart & Vasculature|March 18, 2024
Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantationGeorg Stachel, Madlen Jentzsch, Michelle Oehring, et al.
Bone Marrow Transplantation|October 4, 2022
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or olderDonata Backhaus, Dominic Brauer, Rosmarie Pointner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2021
Extramedullary Clonal Hematopoiesis with Indeterminate PotentialFlorian Ramdohr, Astrid Monecke, Madlen Jentzsch, et al.
American Journal of Hematology|April 3, 2021
Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|July 8, 2022
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantationLisa Herrmann, Lara Bischof, Donata Backhaus, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Blood Cancer Journal|April 30, 2021
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Annals of Hematology|August 31, 2020
Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AMLMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Bone Marrow Transplantation|November 19, 2020
ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
International Journal of Cardiology. Heart & Vasculature|March 18, 2024
Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantationGeorg Stachel, Madlen Jentzsch, Michelle Oehring, et al.
Bone Marrow Transplantation|October 4, 2022
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or olderDonata Backhaus, Dominic Brauer, Rosmarie Pointner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2021
Extramedullary Clonal Hematopoiesis with Indeterminate PotentialFlorian Ramdohr, Astrid Monecke, Madlen Jentzsch, et al.
American Journal of Hematology|April 3, 2021
Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Pageof 11